RESUMEN
PURPOSE: The importance of consistent outpatient follow-up for management of diabetic eye disease has been well-established. The objective of this study was to identify patient factors associated with being lost to follow-up in postsurgical patients after undergoing pars plana vitrectomy for diabetic eye disease. METHODS: The charts of diabetic patients undergoing pars plana vitrectomy for nonclearing vitreous hemorrhage at an academic medical center by a single surgeon between 2012 and 2019 were reviewed. The rates of loss to follow-up during the postoperative period were compared based on patient distance from the clinic and insurance status. RESULTS: A total of 144 patients met inclusion criteria. A total of 45 patients (31.25%) were lost to follow-up during the 3-month postoperative period. The rate of loss to follow-up increased with every postoperative visit and was significantly higher for patients living greater than 30 miles from the clinic versus patients living within 30 miles from the clinic. There was no statistically significant difference in loss to follow-up based on insurance status. CONCLUSION: Increased distance from the clinic presents a challenge to providing safe and effective postsurgical care to diabetic patients. This presents opportunities for comanagement or other creative strategies to improve postsurgical follow-up rates for at-risk patients.
Asunto(s)
Diabetes Mellitus , Retinopatía Diabética , Retinopatía Diabética/complicaciones , Retinopatía Diabética/cirugía , Estudios de Seguimiento , Humanos , Estudios Retrospectivos , Agudeza Visual , Vitrectomía/efectos adversos , Hemorragia Vítrea/cirugíaRESUMEN
INTRODUCTION: Previous studies evaluating the association between clinically diagnosed Alzheimer's disease (AD) and age-related macular degeneration (AMD) have generated conflicting results. This study is the first to assess whether AMD prevalence is higher in AD patients than non-AD controls by using histopathology to definitively diagnose AD. METHODS: This was a retrospective case-control study utilizing diagnostic information extracted from autopsy reports of patients age 75 and above, including 115 with a neuropathological diagnosis of AD and 57 age-matched normal controls. RESULTS: The rate of AMD was not significantly higher in AD cases (53.0%) than in controls (59.6%) (z = 0.820, p = 0.794). AMD severity as determined by Sarks score was similar between AD patients and controls (χ2 = 2.96, p = 0.706). There was also no significant association between Braak stage of AD severity and AMD (χ2 = 4.55, p = 0.602). DISCUSSION: No significant effect of AD diagnosis or pathologic severity on AMD comorbidity was found, suggesting that any shared mechanisms between AMD and AD may be nondeterministic.
Asunto(s)
Enfermedad de Alzheimer/epidemiología , Degeneración Macular/epidemiología , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/patología , Autopsia , Estudios de Casos y Controles , Comorbilidad , Femenino , Histocitoquímica , Humanos , Degeneración Macular/patología , Masculino , North Carolina/epidemiología , Estudios Retrospectivos , Índice de Severidad de la EnfermedadRESUMEN
Purpose: A large body of evidence supports a central role for complement activation in the pathobiology of age-related macular degeneration (AMD), including plasma complement component 5a (C5a). Interestingly, C5a is a chemotactic agent for monocytes, a cell type also shown to contribute to AMD. However, the role monocytes play in the pathogenesis of "dry" AMD and the pharmacologic potential of targeting C5a to regulate these cells are unclear. We addressed these questions via C5a blockade in a unique model of early/intermediate dry AMD and large panel flow cytometry to immunophenotype monocytic involvement. Methods: Heterozygous complement factor H (Cfh+/-) mice aged to 90 weeks were fed a high-fat, cholesterol-enriched diet (Cfh+/-â¼HFC) for 8 weeks and were given weekly intraperitoneal injections of 30 mg/kg anti-C5a (4C9, Pfizer). Flow cytometry, retinal pigmented epithelium (RPE) flat mounts, and electroretinograms were used to characterize anti-C5a treatment. Results: Aged Cfh+/- mice developed RPE damage, sub-RPE basal laminar deposits, and attenuation of visual function and immune cell recruitment to the choroid that was accompanied by expression of inflammatory and extracellular matrix remodeling genes following 8 weeks of HFC diet. Concomitant systemic administration of an anti-C5a antibody successfully inhibited local recruitment of mononuclear phagocytes to the choroid-RPE interface but did not ameliorate these AMD-like pathologies in this mouse model. Conclusions: These results show that immunotherapy targeting C5a is not sufficient to block the development of the AMD-like pathologies observed in Cfh+/-â¼HFC mice and suggest that other complement components or molecules/mechanisms may be driving "early" and "intermediate" AMD pathologies.
Asunto(s)
Anticuerpos Bloqueadores/uso terapéutico , Neovascularización Coroidal/terapia , Complemento C5a/antagonistas & inhibidores , Modelos Animales de Enfermedad , Atrofia Geográfica/terapia , Inmunoterapia , Animales , Colesterol en la Dieta/administración & dosificación , Neovascularización Coroidal/inmunología , Neovascularización Coroidal/patología , Activación de Complemento , Complemento C5a/inmunología , Electrorretinografía , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Atrofia Geográfica/inmunología , Atrofia Geográfica/patología , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos C57BL , Epitelio Pigmentado de la Retina/patologíaRESUMEN
We assessed whether there is a recognisable pattern of facial morphology in photographs of a series of 62 children with idiopathic congenital talipes equinovarus (CTEV). Photographs were scored for a number of facial characteristics by a research team comprising orthopaedic surgeons and clinical geneticists, to identify a subgroup of children with idiopathic CTEV, who shared characteristic facial features. Seven children were identified as having a "CTEV face". There was good correlation between the "CTEV face" and the individual facial features. Repeatability of the assessment was good, and there was good correlation between the geneticists and the orthopaedic surgeons, suggesting that no special training in dysmorphology is required to identify the "CT EV face". There is a subgroup of children with idiopathic CTEV who can be reliably identified by their facial characteristics. The significance of this finding is unclear but it may be of use in clinical genetic studies, and studies of the aetiology of CTEV.